Research analysts at Mizuho increased their target price on shares of AcelRx Pharmaceuticals (NASDAQ: ACRX) from $13.00 to $18.00 in a report released on Wednesday, Analyst Ratings Network.com reports. The firm currently has a “neutral” rating on the stock. Mizuho’s price target would indicate a potential upside of 51.01% from the company’s current price.
ACRX has been the subject of a number of other recent research reports. Analysts at Jefferies Group reiterated a “buy” rating on shares of AcelRx Pharmaceuticals in a research note to investors on Tuesday, June 18th. They now have a $13.00 price target on the stock, up previously from $8.00. Separately, analysts at Guggenheim raised their price target on shares of AcelRx Pharmaceuticals from $7.00 to $15.00 in a research note to investors on Tuesday, May 28th. They now have a “buy” rating on the stock. Finally, analysts at Canaccord Genuity raised their price target on shares of AcelRx Pharmaceuticals from $9.00 to $11.00 in a research note to investors on Wednesday, May 22nd.
One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $13.67.
Shares of AcelRx Pharmaceuticals (NASDAQ: ACRX) opened at 12.27 on Wednesday. AcelRx Pharmaceuticals has a 52 week low of $2.27 and a 52 week high of $13.28. The stock’s 50-day moving average is currently $9.. The company’s market cap is $456.9 million.
AcelRx Pharmaceuticals, Inc is a development-stage company. The Company is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of acute and breakthrough pain.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.